XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues:    
Total revenues $ 371,120 $ 1,327,274
Operating expenses:    
Research and development 39,044,418 19,111,188
General and administrative 13,881,194 7,448,354
Total operating expenses 52,925,612 26,559,542
Loss from operations (52,554,492) (25,232,268)
Other income (expense):    
Interest income 769,237 416,569
Interest expense (513,034) (2,803,755)
Change in fair value of derivative liability 0 (13,221,977)
Gain (loss) on investment in affiliated entities (830,475) 13,181,619
Net unrealized loss on available-for-sale equity securities (847,958) (5,050,092)
Other income (expense), net 8,978 (425,500)
Net loss before share in net loss of Geneos (53,967,744) (33,135,404)
Share in net loss of Geneos (434,387) 0
Net loss (54,402,131) (33,135,404)
Net loss attributable to non-controlling interest 0 594,350
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (54,402,131) $ (32,541,054)
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders    
Basic and diluted (in dollars per share) $ (0.27) $ (0.26)
Weighted average number of common shares outstanding    
Basic and diluted (in shares) 202,414,445 124,623,263
Revenue under collaborative research and development arrangements    
Revenues:    
Total revenues $ 39,615 $ 71,500
Revenue under collaborative research and development arrangements with affiliated entities    
Revenues:    
Total revenues 49,949 1,172,126
Other revenue    
Revenues:    
Total revenues $ 281,556 $ 83,648